166 related articles for article (PubMed ID: 37402881)
1. C/ebpα represses the oncogenic Runx3-Myc axis in p53-deficient osteosarcoma development.
Omori K; Otani S; Date Y; Ueno T; Ito T; Umeda M; Ito K
Oncogene; 2023 Aug; 42(33):2485-2494. PubMed ID: 37402881
[TBL] [Abstract][Full Text] [Related]
2. Runx3 is required for oncogenic Myc upregulation in p53-deficient osteosarcoma.
Otani S; Date Y; Ueno T; Ito T; Kajikawa S; Omori K; Taniuchi I; Umeda M; Komori T; Toguchida J; Ito K
Oncogene; 2022 Jan; 41(5):683-691. PubMed ID: 34803166
[TBL] [Abstract][Full Text] [Related]
3.
Ito K; Otani S; Date Y
Cells; 2023 Apr; 12(8):. PubMed ID: 37190031
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic Runx1-Myc axis in p53-deficient thymic lymphoma.
Date Y; Taniuchi I; Ito K
Gene; 2022 Apr; 819():146234. PubMed ID: 35114276
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic RUNX3: A Link between p53 Deficiency and MYC Dysregulation.
Date Y; Ito K
Mol Cells; 2020 Feb; 43(2):176-181. PubMed ID: 31991537
[TBL] [Abstract][Full Text] [Related]
6. c-Myc is a critical target for c/EBPalpha in granulopoiesis.
Johansen LM; Iwama A; Lodie TA; Sasaki K; Felsher DW; Golub TR; Tenen DG
Mol Cell Biol; 2001 Jun; 21(11):3789-806. PubMed ID: 11340171
[TBL] [Abstract][Full Text] [Related]
7.
Lee YS; Lee JY; Song SH; Kim DM; Lee JW; Chi XZ; Ito Y; Bae SC
Mol Cells; 2020 Oct; 43(10):889-897. PubMed ID: 33115981
[No Abstract] [Full Text] [Related]
8. Role of RUNX3 in bone morphogenetic protein signaling in colorectal cancer.
Lee CW; Ito K; Ito Y
Cancer Res; 2010 May; 70(10):4243-52. PubMed ID: 20442291
[TBL] [Abstract][Full Text] [Related]
9. RUNX3 and p53: How Two Tumor Suppressors Cooperate Against Oncogenic Ras?
Lee JW; van Wijnen A; Bae SC
Adv Exp Med Biol; 2017; 962():321-332. PubMed ID: 28299666
[TBL] [Abstract][Full Text] [Related]
10. Functional relationship between p53 and RUNX proteins.
Bae SC; Kolinjivadi AM; Ito Y
J Mol Cell Biol; 2019 Mar; 11(3):224-230. PubMed ID: 30535344
[TBL] [Abstract][Full Text] [Related]
11. Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination.
Chi XZ; Kim J; Lee YH; Lee JW; Lee KS; Wee H; Kim WJ; Park WY; Oh BC; Stein GS; Ito Y; van Wijnen AJ; Bae SC
Cancer Res; 2009 Oct; 69(20):8111-9. PubMed ID: 19808967
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome.
Yokomizo-Nakano T; Kubota S; Bai J; Hamashima A; Morii M; Sun Y; Katagiri S; Iimori M; Kanai A; Tanaka D; Oshima M; Harada Y; Ohyashiki K; Iwama A; Harada H; Osato M; Sashida G
Cancer Res; 2020 Jun; 80(12):2523-2536. PubMed ID: 32341038
[TBL] [Abstract][Full Text] [Related]
13. Generation of Osteosarcomas from a Combination of Rb Silencing and c-Myc Overexpression in Human Mesenchymal Stem Cells.
Wang JY; Wu PK; Chen PC; Lee CW; Chen WM; Hung SC
Stem Cells Transl Med; 2017 Feb; 6(2):512-526. PubMed ID: 28191765
[TBL] [Abstract][Full Text] [Related]
14. CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc.
Shen S; Yao T; Xu Y; Zhang D; Fan S; Ma J
Mol Cancer; 2020 Oct; 19(1):151. PubMed ID: 33106166
[TBL] [Abstract][Full Text] [Related]
15. S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma.
Shen Y; Zhao S; Wang S; Pan X; Zhang Y; Xu J; Jiang Y; Li H; Zhang Q; Gao J; Yang Q; Zhou Y; Jiang S; Yang H; Zhang Z; Zhang R; Li J; Zhou D
EBioMedicine; 2019 Feb; 40():210-223. PubMed ID: 30587459
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma.
van der Deen M; Taipaleenmäki H; Zhang Y; Teplyuk NM; Gupta A; Cinghu S; Shogren K; Maran A; Yaszemski MJ; Ling L; Cool SM; Leong DT; Dierkes C; Zustin J; Salto-Tellez M; Ito Y; Bae SC; Zielenska M; Squire JA; Lian JB; Stein JL; Zambetti GP; Jones SN; Galindo M; Hesse E; Stein GS; van Wijnen AJ
J Biol Chem; 2013 Jul; 288(29):21307-21319. PubMed ID: 23720736
[TBL] [Abstract][Full Text] [Related]
17. C/EBPalpha regulates SIRT1 expression during adipogenesis.
Jin Q; Zhang F; Yan T; Liu Z; Wang C; Ge X; Zhai Q
Cell Res; 2010 Apr; 20(4):470-9. PubMed ID: 20157332
[TBL] [Abstract][Full Text] [Related]
18. RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC.
Selvarajan V; Osato M; Nah GSS; Yan J; Chung TH; Voon DC; Ito Y; Ham MF; Salto-Tellez M; Shimizu N; Choo SN; Fan S; Chng WJ; Ng SB
Leukemia; 2017 Oct; 31(10):2219-2227. PubMed ID: 28119527
[TBL] [Abstract][Full Text] [Related]
19. E2F activity is essential for survival of Myc-overexpressing human cancer cells.
Santoni-Rugiu E; Duro D; Farkas T; Mathiasen IS; Jäättelä M; Bartek J; Lukas J
Oncogene; 2002 Sep; 21(42):6498-509. PubMed ID: 12226753
[TBL] [Abstract][Full Text] [Related]
20. RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53.
Yamada C; Ozaki T; Ando K; Suenaga Y; Inoue K; Ito Y; Okoshi R; Kageyama H; Kimura H; Miyazaki M; Nakagawara A
J Biol Chem; 2010 May; 285(22):16693-703. PubMed ID: 20353948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]